SOURCE: Sirona Biochem Corp.

Sirona Biochem Corp.

March 21, 2016 08:00 ET

Sirona Biochem Selected to Present at BIO-Europe Spring

VANCOUVER, BC--(Marketwired - March 21, 2016) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO-Europe Spring on April 4, 2016, at 10:00 AM CET at the Kistamässan Convention Center, Stockholm, Sweden.

The main goals for the conference include: seeking strategic partnerships and investment from big pharma to develop new superior drugs using Sirona's innovative platform technology; exploring partnership opportunities with companies that have expressed interest in licensing our SGLT2 inhibitor for type 2 diabetes in markets outside of China (i.e. US, Russia, India) and finding partnerships to assist building the glycoprotein project pipeline.

"We remain focused on advancing our partnering discussions for our skin lightener SBM-TFC-1067, while we are continually expanding our product pipeline," said Attila Hajdu, Chief Business Development Officer of Sirona Biochem.

"Bioavailability and toxicity are the main reasons clinical programs fail in the current pharmaceutical environment, and we have a solution for this problem. That's why we see a strong interest from big pharma in the application of our fluorine chemistry platform across multiple target programs to drive future growth," he added.

BIO-Europe® is the EBD Group's flagship conference, and the premier Spring partnering conference for the biotech industry. It is attended by the most significant global corporations and provides life science companies with high caliber partnering opportunities. BIO-Europe is organized by EBD Group, the leading partnering firm for the global biotechnology industry, in alliance with the Biotechnology Industry Organization (BIO). For more information please visit the conference website at

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant.

For more information please visit

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Contact Information

  • For more information regarding this press release, contact:
    Christopher Hopton, CFO
    Sirona Biochem Corp.
    Phone: 1.604.282.6064